文献速递肿瘤 PET/CT甲状腺核医学

对转移性小叶乳腺癌进行氨基酸转运和PSMA靶向正电子发射断层成像的前瞻性研究

Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-07-08

这项探索性试验纳入20例新发或疑似转移性浸润性小叶癌(ILC)女性,分别行18F-氟环亮氨酸和68Ga-PSMA-11 PET-CT,并与标准影像比较。18F-氟环亮氨酸PET-CT的确认检出率在患者和合并区域水平均显著高于标准影像,也显著高于68Ga-PSMA-11的合并区域水平;真阳性病灶平均SUVmax也显著更高。作者认为ILC氨基酸代谢分子影像值得进一步研究。

要点

  • 18F-氟环亮氨酸PET-CT检出转移的患者数(9/20)和区域数(12/60)均高于标准影像(5/20、5/60)。
  • 68Ga-PSMA-11 PET-CT检出转移的患者数(7/20)和区域数(7/60)与标准影像无显著差异。
  • 真阳性恶性病灶18F-氟环亮氨酸平均SUVmax 5.5±1.8,显著高于68Ga-PSMA-11的3.5±2.7(p=0.021)。

核心结论

  • 在这项探索性试验中,18F-氟环亮氨酸PET-CT对ILC转移的确认检出率显著高于标准影像和68Ga-PSMA-11。
  • 真阳性恶性病灶的平均SUVmax在18F-氟环亮氨酸显著高于68Ga-PSMA-11。
  • 作者认为,该试验的探索性数据提示ILC的氨基酸代谢分子影像值得进一步研究。

研究设计与样本

  • 前瞻性探索性试验纳入20例新发或疑似转移性浸润性小叶癌(ILC)女性。
  • 每例患者在分开的日子接受18F-氟环亮氨酸和68Ga-PSMA-11两次PET-CT扫描。
  • 标准影像为CT/骨扫描(13例)或18F-FDG PET-CT(7例),结果与复合标准真值相关。
  • 确认检出率(cDR)比较采用McNemar检验,平均SUVmax比较采用t检验。
  • 试验为早期(I-II期)临床试验(NCT04750473),由美国国立卫生研究院(R21CA256280)资助。

主要发现

  • 标准影像的确认检出率为5/20例患者、5/60个区域。
  • 68Ga-PSMA-11 PET-CT检出转移为7/20例患者、7/60个区域。
  • 18F-氟环亮氨酸PET-CT检出转移为9/20例患者、12/60个区域。
  • 18F-氟环亮氨酸PET-CT的cDR在患者水平和合并区域水平均显著高于标准影像。
  • 68Ga-PSMA-11与标准影像之间无显著差异;18F-氟环亮氨酸cDR在合并区域水平也显著高于68Ga-PSMA-11。

关键数值与推荐

  • 真阳性转移和原发病灶中,18F-氟环亮氨酸(n=18)平均SUVmax为5.5±1.8,68Ga-PSMA-11(n=11)为3.5±2.7,p=0.021。
  • 18F-氟环亮氨酸PET-CT的cDR在患者和合并区域水平显著高于标准影像,而68Ga-PSMA-11与标准影像无显著差异。
  • 18F-氟环亮氨酸cDR在合并区域水平显著高于68Ga-PSMA-11。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为探索性试验,作者在结论中提出氨基酸代谢分子影像在ILC患者中值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore the feasibility of imaging amino-acid transport and PSMA molecular pathways in the detection of metastatic breast invasive lobular carcinoma (ILC) and if there is superior detection compared to standard-of-care imaging [computed tomography (CT)/bone scan, or 18F-FDG positron-emission-tomography (PET)-CT]. METHODS: 20 women with de-novo or suspected metastatic ILC underwent two PET-CT scans with 18F-fluciclovine and 68Ga-PSMA-11 on separate days. Uptake per patient and in 3 regions per patient - ipsilateral axillary lymph node (LN), extra-axillary LN (ipsilateral supraclavicular or internal mammary), or distant sites of disease - was compared to standard-of-care imaging (CT/bone scan in 13 patients and 18F-FDG PET-CT in 7 patients). Results were correlated to a composite standard of truth. Confirmed detection rate (cDR) was compared using McNemar's test. Mean SUVmax of 18F-fluciclovine and 68Ga-PSMA-11 in the most avid lesion for each true positive metastatic region and intact primary lesion were compared by t-test. RESULTS: The cDR for standard-of-care imaging was 5/20 patients in 5/60 regions. 68Ga-PSMA-11 PET-CT detected metastasis in 7/20 patients in 7/60 regions. 18F-fluciclovine PET-CT detected metastasis in 9/20 patients in 12/60 regions. The cDR for 18F-fluciclovine PET-CT was significantly higher versus standard-of-care imaging on the patient and combined region levels, while there were no significant differences between 68Ga-PSMA-11 and standard-of care imaging. 18F-fluciclovine cDR was also significantly higher than 68Ga-PSMA-11 on the combined region level. Mean SUVmax for true positive metastatic and primary lesions with 18F-fluciclovine (n = 18) was significantly greater than for 68Ga-PSMA-11 (n = 11) [5.5 ± 1.8 versus 3.5 ± 2.7 respectively, p = 0.021]. CONCLUSION: In this exploratory trial, 18F-fluciclovine PET-CT has a significantly higher cDR for ILC metastases compared to standard-of-care imaging and to 68Ga-PSMA-11. Mean SUVmax for true positive malignancy was significantly higher with 18F-fluciclovine than for 68Ga-PSMA-11. Exploratory data from this trial suggests that molecular imaging of amino acid metabolism in patients with ILC deserves further study. CLINICAL TRIAL REGISTRATION: Early phase (I-II) clinical trial (NCT04750473) funded by the National Institutes of Health (R21CA256280).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mushtaq A, Lawal IO, Muzahir S, et al. Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38976035. doi:10.1007/s00259-024-06830-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。